Keywords: gsk, drops, avandia, deal, b-ms, uk, headquartered
GSK drops Avandia deal with B-MS
Article | 12 August 2002
UK headquartered GlaxoSmithKline has terminated its US marketing dealwith Bristol-Myers Squibb for the antidiabetic drug Avandia (rosiglitazone), effective August 20, a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
